Daily Archives: September 25, 2020

AKWEL: NET EARNINGS OF €20.2 MILLION IN THE FIRST HALF OF 2020

Thursday 24 September 2020 NET EARNINGS OF €20.2 MILLION IN THE FIRST HALF OF 2020 AKWEL (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, published its 2020 half-yearly results. Consolidated data – in € millions 30.06.2020 30.06.2019 Var. in % Revenue 387.0 566.5 -31.7% EBITDA 60.0 66.6

Kinesio Tape for dogs?

You betcha! Albuquerque, New Mexico, USA, Sept. 24, 2020 (GLOBE NEWSWIRE) — You may have heard about Kinesio Taping on people, from elite athletes to medical patients. Maybe you know about someone who uses Kinesio Equine Taping on a horse. Now there is a Kinesio Tape specially designed and formulated for your furry friend. Kinesio

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

Clinical trial to enroll up to 10,000 volunteers across the UK to assess whether NVX-CoV2373 is effective in the prevention of COVID-19 GAITHERSBURG, Md., Sept. 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase

Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)

La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) — Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers. — Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous